← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $166B	1,993	+24	+1%	$152B
2	2 Amgen AMGN $230B	1,474	+38	+3%	$91.2B
3	3 Eli Lilly LLY $1.08T	1,180	+28	+2%	$66B
4	4 Becton Dickinson BDX $51.5B	997	+39	+4%	$30.4B
5	5 McKesson MCK $114B	943	+6	+0.6%	$36.1B
6	6 Teva Pharmaceutical Industries Limited TEVA $47.5B	813	-24	-3%	$29.9B
7	7 Conagra Brands CAG $6.61B	686	+15	+2%	$16B
8	8 Regeneron Pharmaceuticals REGN $80.1B	542	-8	-1%	$25.3B
9	9 Novo Nordisk NVO $168B	530	-6	-1%	$10.4B
10	10 DaVita DVA $11.5B	502	+27	+6%	$13.5B
11	11 AstraZeneca AZN $251B	398	+8	+2%	$8.72B
12	12 ResMed RMD $33.1B	362	-13	-3%	$5.5B
13	13 West Pharmaceutical WST $26.4B	289	+38	+15%	$5.07B
14	14 Accendra Health ACH $24.1M	283	-3	-1%	$2.3B
15	15 Opko Health OPK $1.02B	245	-14	-5%	$1.08B
16	16 Herbalife HLF $1.49B	242	+15	+7%	$5.85B
17	17 DELISTED CATALENT, INC. CTLT	186	+12	+7%	$2.93B
18	18 Tootsie Roll Industries TR $2.87B	175	+4	+2%	$552M
19	19 Fresenius Medical Care FMS $11.5B	170	-3	-2%	$622M
20	20 Dr. Reddy's Laboratories RDY $10.6B	157	-3	-2%	$1.39B
21	21 Alaunos Therapeutics TCRT $5.26M	154	+11	+8%	$328M
22	22 Medifast MED $132M	153	+20	+15%	$344M
23	23 DELISTED WW International WW	153	+4	+3%	$683M
24	24 MannKind Corp MNKD $971M	147	-6	-4%	$108M
25	25 Lexicon Pharmaceuticals LXRX $712M	138	+6	+5%	$1.59B